Extended Data Fig. 4: Forest Plot of PFS (per Investigator Assessment) in Key Patient Subgroups. | Nature Medicine

Extended Data Fig. 4: Forest Plot of PFS (per Investigator Assessment) in Key Patient Subgroups.

From: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Extended Data Fig. 4: Forest Plot of PFS (per Investigator Assessment) in Key Patient Subgroups.

Data cutoff: November 30, 2023; the protocol-specified final analysis of PFS. Statistical analysis was not performed when the number of patients in the subgroup was less than 10% of the total patients. HRs along with 95% CIs were estimated using an unstratified Cox proportional hazards model in each subgroup. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; NE, not estimable; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; PFS, progression-free survival; sac-TMT, sacituzumab tirumotecan; TNBC, triple-negative breast cancer.

Back to article page